Hongnan Mo

机构：Chinese Academy of Medical Sciences & Peking Union Medical College, Peking University, National Cancer Center, Peking University Cancer Hospital · ORCID：0000-0002-2887-7985

发表论文 124 篇 · 总被引 2625 次 · h-index 21

代表论文

• Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer (2025 · Cancer Cell · 被引 130)
• Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer: the phase 2 NeoSAC trial (2025 · Signal Transduction and Targeted Therapy · 被引 16)
• The ideal strategies of antibody‒drug conjugate sequential treatment in HER2-expressing metastatic breast cancer: A multi-center real-world study (2025 · The Breast · 被引 9)
• Predictive circulating biomarkers of the response to anti‐PD‐1 immunotherapy in advanced HER2 negative breast cancer (2025 · Clinical and Translational Medicine · 被引 6)
• Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study (2024 · BMC Cancer · 被引 5)
• Comparative efficacy of anthracycline-free and anthracycline-containing neoadjuvant chemoimmunotherapy regimens for triple-negative breast cancer (2024 · Translational Oncology · 被引 4)